Tcelltech Inc.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103(Tcelltech Inc.)은 B7-H3 표적 세포·유전자 치료로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies.
B7-H3
Solid Tumors
Recruiting
CAR T-cell and ADC-based approaches
s
Viral vectors, used in all licensed products, provide stable genomic integration and durable
humanized mouse model
novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
payloads, while introducing distinct safety and persistence profiles
biomarker in various malignancies
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Tcelltech Inc.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103(Tcelltech Inc.)은 B7-H3 표적 세포·유전자 치료로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies.
B7-H3
Solid Tumors
Recruiting
CAR T-cell and ADC-based approaches
s
Viral vectors, used in all licensed products, provide stable genomic integration and durable
humanized mouse model
novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
payloads, while introducing distinct safety and persistence profiles
biomarker in various malignancies
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.